POS1274 A SINGLE CENTER COVID-19 VACCINE EXPERIENCE IN FAMILIAL MEDITERRANEAN FEVER PATIENTS
Authors: S. C. Güven, Ö. Karakaş, E. Atalar, H. E. Konak, P. Akyüz Dağli, E. Kayacan Erdogan, B. Armagan, K. Gok, I. Dogan, Y. Maraş, A. Erden, S. Erten, O. Küçükşahin, A. Omma
Journal: Annals of the Rheumatic Diseases (2022)

Background To prevent COVID-19 disease SARS-CoV 2 vaccines put into use worldwide with emergency use authorizations despite ongoing safety concerns. Since pyrin mediated inflammasome response is dysregulated in FMF, exposure to SARS-CoV 2 proteins via vaccination may potentially trigger inflammation, leading to attacks and/or increased rate of adverse events (AE). Objectives Aim of this study to investigate frequency of adverse events and attacks related to vaccination in recipients of CoronaVac and BNT162b2 comparatively in our FMF patients. Methods Data regarding, number of vaccine doses, types of vaccines (CoronaVac or BNT162b2), presence of AEs and/or FMF attacks after any vaccine dose within a month, history of COVID-19 infection before or after vaccination, adherence to FMF treatment during vaccination were collected from hospital database or via telephone. Results A total of 161 vaccinated FMF patients were included. Mean ± SD age was 40.5 ± 11.7 years. 57.1% was female. 10.6% of the patients had chronic kidney disease and 9.3% had amyloidosis. Most common MEFV mutations were M694V heterozygous (27%) and M694V homozygous (21.6%). 93.2% of the patients were under colchicine, 21.8% under anti-interleukin 1 agents, 2.5% under TNF-a inhibitors. 96.3% of the patients adhered to FMF treatment during vaccination. Vaccination properties and data regarding adverse events are presented in Table 1. 57.8% of patients reported to suffer from an AE/attack after a vaccine dose. Number of patients with AE after BNT162b2 was significantly higher (p&lt;0.001). None of the patients had severe AEs. 39 patients had COVID-19 infection prior to primary vaccination. 61.5% of these suffered from an adverse reaction/attack after vaccination, in comparison to 56.6% of the patients without prior COVID-19 infection (p=0.584). When patients with and without AEs/attacks were compared, no significant differences were observed regarding age, gender, body mass index, comorbidities, FMF treatments and total vaccine doses. Table 1. Adverse events and FMF attacks in a total of 161 vaccine recipients BNT162b2 CoronaVac p Total vaccine doses, n 213 140 Patients ever vaccinated with BNT162b2 and CoronaVac, n (% ) 117 (72.7) 67 (41.6) Dose per patient, median (min-max ) 2 (1-4) 2 (1-4) Patients with primary vaccination completed with BNT162b2 or CoronaVac, n (%)* 88 (54.7) 57 (35.4) Patients with a booster with BNT162b2 or CoronaVac, n (% ) 23 (14.2) 14 (8.6) Patients vaccinated with BNT162b2 or CoronaVac alone, n(% ) 94 (58.4) 44 (27.3) Patients with an adverse event after any vaccine dose of n (% ) ¶ 64/117 (54.7) 20/67 (29.9) &lt;0.001 Adverse events, n (% ) ¶ Fever 13 (11.1) 6 (9.0) 0.644 Malaise 21 (17.9) 4 (6.0) 0.023 Local pain/arm pain 17 (14.5) 4 (6.0) 0.079 Arthralgia 19 (16.2) 4 (6.0) 0.043 Myalgia 6 (5.1) 0 (0.0) 0.059 Headache 11 (9.4) 0 (0.0) 0.010 Nausea 6 (5.1) 1 (1.5) 0.215 Vomiting 4 (3.4) 1 (1.5) 0.439 Others 22 (18.9) 7 (10.4) Patients with FMF attack within one month after any vaccine dose, n (% ) ¶ 26 (22.2) 13 (19.4) 0.653 Time from vaccine dose to FMF attack, days, median (IQR ) 7.0 (12.5) 10.0 (13.5) 0.758 *9.9 % of the patients had only single dose of either vaccine, ¶ Over 117 ever vaccinated with BNT162b2 and 67 ever with CoronaVac Conclusion We observed considerable number of FMF patients suffered from vaccine related AEs/attacks, particularly with BNT162b2. However, no serious AE was detected. Demographics, clinical characteristics and prior history of vaccination did not significantly affect AE/attack occurrence. Acknowledgements I have no acknowledgements to declare. Disclosure of Interests None declared